Search

Harmony Biosciences Holdings Inc

Fermé

SecteurSoins de santé

41.21 0.37

Résumé

Variation du prix de l'action

24h

Actuel

Min

40.65

Max

41.67

Chiffres clés

By Trading Economics

Revenu

43M

75M

Ventes

46M

261M

P/E

Moyenne du Secteur

13.673

56.597

BPA

1.28

Marge bénéficiaire

28.87

Employés

293

EBITDA

53M

102M

Dividendes

By Acuity

Prochains Résultats

3 nov. 2026

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

400M

2.5B

Ouverture précédente

40.84

Clôture précédente

41.21

Sentiment de l'Actualité

By Acuity

67%

33%

289 / 339 Classement par Healthcare

Harmony Biosciences Holdings Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

11 sept. 2026, 22:56 UTC

Harmony Biosciences Holdings Inc is trading higher in after-market hours, remaining above its 20-day moving average and near the upper end of its one-month range.

9 sept. 2026, 20:07 UTC

Harmony Biosciences Holdings Inc shares are lower during Wednesday's session, with no specific news identified to explain the decline. The stock remains above its 20-day moving average.

8 sept. 2026, 20:13 UTC

Harmony Biosciences Holdings Inc is higher in after-market trading, supported by solid performance above its 20-day moving average and nearing its one-month trading range.

3 sept. 2026, 20:02 UTC

News
Event

Harmony Biosciences announced it will present EPX-100 data at a future congress. Shares are trading lower, reversing from an earlier session high.

2 sept. 2026, 20:01 UTC

Harmony Biosciences Holdings Inc is higher today, reflecting positive market response despite no specific news. Broader market context includes slower job growth reported by ADP.

1 sept. 2026, 23:01 UTC

Harmony Biosciences Holdings Inc shares are higher in after-market trading, continuing an upward trend from three consecutive sessions of gains. No specific news was identified.

31 août 2026, 22:06 UTC

Harmony Biosciences shares are higher in after-market trading, rebounding from an initial dip amid geopolitical tensions affecting broader market conditions.

28 août 2026, 20:07 UTC

Harmony Biosciences Holdings Inc shares are lower during Friday's session, continuing a decline since Thursday's close amid no specific news to explain the downturn.

27 août 2026, 19:56 UTC

News

Harmony Biosciences will participate in the 2026 Cantor Global Healthcare Conference. Shares are higher today, reflecting positive market sentiment since Wednesday's close.

26 août 2026, 20:08 UTC

News

Wolfe Research initiated coverage on Harmony Biosciences with an Outperform rating and a $60 price target, contributing to higher shares during Wednesday's session.

25 août 2026, 19:26 UTC

Shares of Harmony Biosciences Holdings Inc. are modestly higher, trading within a narrow range amid routine performance during Tuesday's session.

24 août 2026, 21:01 UTC

Harmony Biosciences Holdings Inc is trading higher in after-market hours, reflecting a broader rebound in the bond market as Treasury yields decline.

21 août 2026, 22:31 UTC

Harmony Biosciences Holdings Inc. is trading higher in after-market hours, reaching the upper end of its one-month range and above the 20-day moving average.

20 août 2026, 23:31 UTC

Harmony Biosciences Holdings Inc shares are higher in after-market trading, supported by strong momentum above the 20-day moving average and within its one-month range.

19 août 2026, 19:56 UTC

Harmony Biosciences Holdings Inc. is trading higher, reaching a session high and remaining above its 20-day moving average during Wednesday's session.

14 août 2026, 19:46 UTC

Harmony Biosciences shares are lower as the Pharmaceuticals sub-sector declines. The stock remains above its 20-day moving average, indicating some underlying strength.

13 août 2026, 22:51 UTC

Harmony Biosciences shares are rising in after-market trading, supported by favorable macroeconomic indicators and a broader trend in major averages closing higher.

11 août 2026, 19:21 UTC

Harmony Biosciences Holdings Inc. is trading higher today, continuing its upward trajectory since Monday's close amid broader market trends and rising oil prices.

10 août 2026, 19:46 UTC

Harmony Biosciences Holdings Inc is trading higher, continuing its upward trend since Friday. The stock remains above its 20-day moving average.

7 août 2026, 20:06 UTC

Shares of Harmony Biosciences Holdings Inc. are lower amid broader market declines and decreasing Treasury yields following recent economic data.

6 août 2026, 23:51 UTC

Harmony Biosciences Holdings Inc shares declined during after-market hours, struggling to maintain earlier gains amid a lack of specific news to explain the movement.

5 août 2026, 20:03 UTC

Social Media
Event
News

Harmony Biosciences shares are lower despite new Phase 1 data on BP-205. Truist maintains a Hold rating and raises the price target to $34.

4 août 2026, 20:04 UTC

Social Media
News
Event

Harmony Biosciences reported strong Q2 earnings of $75.43 million and reaffirmed 2026 revenue guidance, with shares trading sharply higher during the session.

3 août 2026, 23:11 UTC

Harmony Biosciences shares are higher in after-hours trading, supported by positive sentiment from the Institute for Supply Management's manufacturing PMI report.

1 août 2026, 00:01 UTC

Shares of Harmony Biosciences Holdings Inc are higher in after-market trading, reflecting notable strength since Friday's close without any specific news driving the move.

31 juil. 2026, 23:21 UTC

Harmony Biosciences Holdings Inc. is trading higher during after-market hours, reflecting steady price increases since Friday's close, despite no specific news identified.

28 juil. 2026, 18:26 UTC

News

Shares of Harmony Biosciences are lower despite a 30% revenue increase for WAKIX, as market sentiment reflects concerns over potential cash flow erosion.

27 juil. 2026, 19:41 UTC

Shares of Harmony Biosciences Holdings Inc. are higher today, breaking from a recent upward trend despite the absence of specific company news.

24 juil. 2026, 17:06 UTC

Shares of Harmony Biosciences Holdings Inc. are lower today, continuing a decline since Thursday's close, despite earlier reaching a session high.

22 juil. 2026, 20:01 UTC

News

Harmony Biosciences Holdings Inc is trading lower despite preliminary Q2 2026 results showing record net product revenue of approximately $261 million, a 30% year-over-year increase.

Comparaison

Variation de prix

Harmony Biosciences Holdings Inc prévision

Note du Consensus

By TipRanks

Achat Modéré

9 ratings

4

Achat

4

Maintien

1

Vente

Sentiment

By Acuity

289 / 339Classement par Soins de santé

Sentiment de l'Actualité

Indications Baissières

Volatilité

Inférieur à la moyenne

Changement du Volume d'Actualités (RCV)

Inférieur à la moyenne

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Harmony Biosciences Holdings Inc

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also offers HBS-102, a melanin-concentrating hormone receptor 1 for MCH neurons. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.
help-icon Live chat